Publications by authors named "C M Maillard"
Background: Cervicitis, an infectious or noninfectious inflammation of the cervix, encompasses a wide range of clinical conditions, from asymptomatic infections to severe lesions, making its diagnosis difficult. Acute cervicitis may develop into pelvic inflammatory disease. In patients with cervicitis, current guidelines recommend testing for herpes simplex virus when external genital lesions are present.
View Article and Find Full Text PDFArticle Synopsis
- Avelumab is a treatment approved for metastatic Merkel cell carcinoma (mMCC) and this study focused on its effectiveness in patients in France who received it as a second-line or later treatment.
- The study analyzed data from 180 patients, revealing a median overall survival of 14.6 months after starting avelumab and a 40.5% survival rate at 24 months.
- The results showed that real-world outcomes for avelumab align with previous clinical trial findings, reinforcing its recommendation as a standard treatment for mMCC.
Background: This case describes the youngest patient documented in the literature who presented with a giant hydatidiform mole, effectively addressed through conservative treatment.
Case Presentation: Our department received a 20-year-old Caucasian patient who was admitted due to significant metrorrhagia in an undisclosed pregnancy. During examination, we identified a massive, highly vascularized hydatidiform mole measuring 22 cm (cm).
Introduction: Surgery is the cornerstone of ovarian cancer treatment. However, surgery and perioperative inflammation have been described as potentially pro-metastagenic. In various animal models and other human cancers, intraoperative administration of non-steroidal anti-inflammatory drugs (NSAIDs) appears to have a positive impact on patient outcomes.
View Article and Find Full Text PDFChimeric antigen receptor (CAR) T-cell therapy for multiple myeloma targeting B-cell maturation antigen (BCMA) induces high overall response rates. However, relapse still occurs and novel strategies for targeting multiple myeloma cells using CAR T-cell therapy are needed. SLAMF7 (also known as CS1) and CD38 on tumor plasma cells represent potential alternative targets for CAR T-cell therapy in multiple myeloma, but their expression on activated T cells and other hematopoietic cells raises concerns about the efficacy and safety of such treatments.
View Article and Find Full Text PDF